Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,528.29
(
-0.80%
)
US TECH 100
23,394.40
(
-0.53%
)
Dow Jones
45,778.04
(
-0.93%
)
Brent Oil
100.46
(
3.79%
)
Bitcoin
70,324.00
(
-0.81%
)
News Focus
News Focus
Post# of 257275
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

jq1234

Send PM Follow Ignore
Followers 69
Posts 4516
Boards Moderated 0
Alias Born 12/13/2009

jq1234

Re: mcbio post# 107528

Friday, 10/29/2010 9:52:44 PM

Friday, October 29, 2010 9:52:44 PM

Post# of 257275

I still am curious as to why Shire walked away from Amigal in Phase 3



Shire walked away because Pilcera for Gaucher failed phase II study. Gaucher has much bigger market than Fabry, and the failure probably raised question whether it would succeed in Fabry as well. In addition, Shire already had ERT in both Gaucher (approved this year) and Fabry (pending at FDA).
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today